Macquarie Group’s Immunic IMUX Stock Holding History

Macquarie Group’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4	Closed	-$9K	–	2254
2017 Q4	$9K	Buy	+4	New	+$8.84K	﹤0.01%	2275

Other funds holding IMUX

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Macquarie Group's IMUX Position: Q1 2018 in Review

Macquarie Group sold out of Immunic (IMUX) in Q1 2018, closing a stake of 4 shares — an estimated $9K sold.

Macquarie Group first reported a position in IMUX in Q4 2017 and held it in 1 quarter. The position peaked at $9K in Q4 2017. 58 funds tracked by Wall St. Rank hold IMUX as of Q1 2018.

Macquarie Group reported no remaining Immunic position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 4 Immunic shares in Q1 2018, an estimated $9K.
Macquarie Group first reported a position in Immunic in Q4 2017 and held it in 1 quarter.
Macquarie Group's Immunic position peaked at $9K in Q4 2017.
58 funds tracked by Wall St. Rank held Immunic as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.